The influence of diabetes mellitus and insulin resistance on receptor CD36 expression. Part II. The role of receptor CD36 in the pathomechanism of diabetes complications;Wpływ cukrzycy i insulinoopornos̈ci na ekspresję receptora CD36. Częs̈ć II. Udział receptora CD36 w patomechanizmie powikłań cukrzycy

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 152-162

  Kuliczkowska Płaksej, Justyna ^a   Bednarek Tupikowska, Grazyna ^a   Płaksej, Rafał ^b   Filus, Alicja ^a  

^a Katedra i Klinika Endokrynologii   (Poland)

^b Medical University of Lublin Katedra i Klinika Kardiologii   (Poland)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetes mellitus; Insulin resistance; OxLDL; Scavenger receptor CD36

Indexed keywords

CD36 ANTIGEN;

ANIMAL; ATHEROSCLEROSIS; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENGLISH ABSTRACT; HUMANS; INSULIN RESISTANCE; RISK FACTORS;

EID: 33846284194     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Adachi H., Tsujimoto M.: FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. J. Biol. Chem., 2002; 277: 34264-34270
2. Aitman T.J.: CD36, insulin resistance, and coronary heart disease. Lancet, 2001; 357: 651-652
3. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., Al-Majali K.M., Trembling P.M., Mann C.J., Shoulders C.C., Graf D., St. Lezin E., Kurtz T.W., Kren V., Pravenec M., Ibrahimi A., Abumrad N.A., Stanton L.W., Scott J.: Identification of Cd36 (fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet., 1999; 21: 76-83
4. Alberti G., Zimmet J., Shaw J., Grundy S.M., Aschner P., Balkau B., Bennett P., Boyko E., Brunzell J., Chan J., DeFronzo R., Despres J.-P., Groop L., Laakso M., Mbanya J.C., Pan C.Y., Ramachandran A., Standl E., Stern M., Tuomilehto J., Unwin N., Lefebvre P., Barter P., Matsuzawa Y. The IDF consensus worldwide definition of the metabolic syndrome. Http://www.idf.org/webdata/docs/MetSyndrome-FINAL.pdf (16.02.2006)
5. Armstrong L.C., Bornstein P.: Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol., 2003; 22: 63-71
6. Aydin A., Orhan H., Sayal A., Ozata M., Sahin G., Isimer A.: Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effect of glycemic control. Clin. Biochem., 2001; 34: 65-70
7. Baynes J.W., Thorpe S.R.: Role of oxidative stress in diabetic comlications: A new perspective on an old paradigm. Diabetes, 1999; 48: 1-9
8. Brownlee M.: The pathological implications of protein glycation. Clin. Invest. Med., 1995; 18: 275-281
9. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H.: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA, 1993; 90: 6434-6438
10. Camp H.S., Tafuri S.R.: Regulation of peroxisome proliferator-activated receptor g activity by mitogen-activated protein kinase. J. Biol. Chem., 1997; 272: 10811-10816
11. Carlquist J.F., Muhlestein J.B., Horne B.D., Hart N.I., Lim T., Habashi J., Anderson J.G., Anderson J.L.: Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36. Atheroscler., 2004; 177: 53-59
12. Carter A.M., Grant P.J.: Vascular homeostasis, adhesion molecules and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet. Med., 1997; 14: 423-432
13. Ceriello A., Bortolotti N., Motz E., Crescentini A., Lizzio S., Russo A., Tonutti L., Taboga C.: Meal-generated oxidative stress in type 2 diabetic patients. Diab. Care, 1998; 21: 1529-1533
14. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M.: PPAR-g dependent and independent effects on macrophage-gen expression in lipid metabolism and inflammation. Nat. Med., 2001; 7: 48-52
15. Chen S., Khan Z.A., Barbin Y., Chakrabarti S.: Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic. Res., 2004; 38: 1301-1310
16. Cohen M.P., Lautenslager G., Shea E.: Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur. J. Clin. Chem. Clin. Biochem., 1993; 31: 707-713
17. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., Law R.E.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 365-371
18. Connelly M.A., Klein S.M., Azhar S., Abumrad N.A., Williams D.L.: Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J. Biol. Chem., 1999; 274: 41-47
19. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J.: Hyperinsulinemia as an independent risk factor for ischaemic heart disease. N. Engl. J. Med., 1996; 334: 952-957
20. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Tatoń J.: PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial. Lancet, 2005; 366: 1279-1289
21. Dressman J., Kincer J., Matveev S.V., Guo L., Greenberg R.N., Guerin T., Meade D., Li X.A., Zhu W., Uittenbogaard A., Wilson M.E., Smart E.J.: HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest., 2003; 111: 389-397
22. Evans J.M., Wang J., Morris A.D.: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Brit. Med. J., 2002; 324: 939-942
23. Farhangkhoee H., Khan Z.A., Barbin Y., Chakrabarti S.: Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia, 2005; 48: 1401-1410
24. Farhangkhoee H., Khan Z.A., Mukherjee S., Cukiernik M., Barbin Y.P., Karmazyn M., Chakrabarti S.: Heme oxygenase in diabetes-induced oxidative stress in the heart. J. Mol. Cell. Cardiol., 2003; 35: 1439-1448
25. Febbraio M., Abumrad N.A., Hajjar D.P., Sharma K., Cheng W., Pearce S.F.A., Silverstein R. L.: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem., 1999; 274: 19055-19062
26. Febbraio M., Guy E., Silverstein R.L.: Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2004; 24: 2333-2338
27. Febbraio M., Hajjar D.P., Silverstein R.L.: CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, infammation, and lipid metabolism. J. Clin. Invest., 2001; 108: 785-791
28. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hasen S.L., Hoff H.F., Sharma K., Silverstein R.L.: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest., 2000; 105: 1049-1056
29. Fontbonne A.M., Eschwege E.M.: Insulin and cardiovascular disease. Paris Prospective Study. Diab. Care, 1991; 14: 461-469
30. Furuhashi M., Ura N., Nakata T., Shimamoto K.: Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diab. Care, 2003; 26: 471-474
31. Gilbert R.E., Cooper M.E.: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int., 1999; 56: 1627-1637
32. Giugliano D., Ceriello A., Paolisso G.: Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism, 1995; 44: 363-368
33. Greenwalt D.E., Lipsky R.H., Ockenhouse C.F., Ikeda H., Tandon N.N., Jamieson G.A.: Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine. Blood, 1992; 80: 1105-1115
34. Greenwalt D.E., Scheck S.H., Rhinehart-Jones T.: Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J. Clin. Invest., 1995; 96: 1382-1388
35. Griffin E., Re A., Hamel N., Fu C., Bush H., McCaffrey, Asch A.S.: A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat. Med., 2001; 7: 840-846
36. Haffner S., Taegtmeyer H.: Epidemic obesity and the metabolic syndrome. Circulation, 2003; 108: 1541-1545
37. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998; 339: 229-234
38. Haffner S.M., Mykkanen L., Festa A., Burke J.P., Stern M.P.: Insulinresistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation, 2000; 101: 975-980
39. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., Patterson J.K.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA, 1990; 263: 2893-2898
40. Han J., Hajjar D.P., Tauras J.M., Feng J., Gotto A.M., Nicholson A.C.: Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scevenger, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J. Biol. Chem., 2000; 275: 1241-1246
41. Han J., Hajjar D.P., Tauras J.M., Nicholson A.C.: Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J. Lipid Res., 1999; 40: 830-838
42. Heine R.J., Dekker J.M.: Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia, 2002; 45: 461-475
43. Hennes M.M., O'Shaughnessy I.M., Kelly T.M., LaBelle P., Egan B.M., Kissebah A.H.: Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension, 1996; 28: 120-126
44. Hirano K., Kuwasako T., Nakagawa-Toyama Y., Janabi M., Yamashita S., Matsuzawa Y.: Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc. Med., 2003; 13: 136-141
45. Ho J.E., Paultre F., Mosca L.: Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke, 2003; 34: 2812-2816
46. Hopfner R.L., Gopalakrishnan V.: Endothelin: emerging role in diabetic vascular comlications. Diabetologia, 1999; 42: 1383-1394
47. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., Manson J.E.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diab. Care, 2002; 25: 1129-1134
48. Hu G., Qiao Q., Tuomilehto J., Eliasson M., Feskens E.J., Pyorala K. For the DECODE Insulin Study Group: Plasma insulin and cardiovascular mortality in non-diabetic European men and women: A metaanalysis of data from eleven prospective studies. Diabetologia, 2004; 47: 1245-1256
49. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., Glass C.K.: Interleukin-4-dependent production of PPAR-g ligands in macrophages by 12/15-lipoxygenase. Nature, 1999; 400: 378-382
50. Hughes R.I., Aitman T.J.: Genetics of the metabolic syndrome and implications for therapy. International Congress Series, 2004; 1262: 224-229
51. Huh H.Y., Pearce S.F., Yesner L.M., Silverstein R.L.: Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood, 1996; 87: 2020-2028
52. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H.: High glucose leveland free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000; 49: 1939-1945
53. Kamalvand G., Pinard G., Ali-Khan Z.: Heme-oxygenase-1 response, a marker of oxidative stress, in a mouse model of AA amyloidosis. Amyloid, 2003; 10: 151-159
54. Kashiwagi H., Tomiyama Y., Kosugi S., Shiraga M., Lipsky R.H., Kanayama Y., Kurata Y., Matsuzawa Y.: Identification of the molecular defects in a subject with type I CD36 deficiency. Blood, 1994; 83: 3545-3552
55. Klein R.L., Laimins M., Lopes-Virella M.F.: Isolation, characterisation, and metabolism of the glycated and non-glycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes, 1995; 44: 1093-1098
56. Kowalska I., Prokop J., Bachórzewska-Gajewska H., Telejko B., Kinalska I., Kochman W., Musial W.: Disturbances of glucose metabolism in men referred for coronary arteriography. Post-load glycemia as predictor for coronary atherosclerosis. Diabetes Care, 2001; 24: 897-901
57. Kuniyasu A., Ohgami N., Hayashi S., Miyazaki A., Horiuchi S., Nakayama H.: CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett., 2003; 537: 85-90
58. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., Rhee J.S., Silverstein R., Hoff H., Freeman M.W.: Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem., 2002; 277: 49982-49988
59. Kunt T., Forst T., Fruh B., Flohr T., Schneider S., Harzer O., Pfutzner A., Engelbach M., Lobig M., Beyer J.: Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Exp. Clin. Endocrinol. Diabetes., 1999; 107: 252-256
60. Lam M.C., Tan K.C., Lam K.S.: Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 maccrophages. Atherosclerosis, 2004; 177: 313-320
61. Lamharzi N., Renard C.B., Kramer F., Pennathur S., Heinecke J.W., Chait A., Bornfeldt K.E.: Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions. Potential role of glucose-oxidized LDL. Diabetes, 2004; 53: 3217-3225
62. Lebovitz H.E.: Effect of the postprandial state on nontraditional risk factors. Am. J. Cardiol., 2001; 88(Suppl.): 20H-25H
63. Lee C.D., Folsom A.R., Pankow J.S., Brancati F.L., Atherosclerosis Risk in Communities (ARIS) Study Investigators: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation, 2004; 109: 855-860
64. Liang C.P., Han S., Okamoto H., Carnemolla R., Tabas I., Accili D., Tall A.R.: Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest., 2004; 113: 764-773
65. Listenberger L.L., Ory D.S., Shaffer J.E.: Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J. Biol. Chem., 2001; 276: 14890-14895
66. Mangalmurti S.S., Farkouh M.E.: Cardiovascular disease in diabetics: pharmacology and revascularisation. Mount Sinai J. Med., 2004; 71: 375-383
67. Miyaoka K., Kuwasako T., Hirano K., Nozaki S., Yamashita S., Matsuzawa Y.: CD36 deficiency associated with insulin resistance. Lancet, 2001; 357: 686-687
68. Moore K.Y., Rosen E.D., Fitzgeralt M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., Freeman M.W.: The role of PPAR-g in macrophage differentiation and cholesterol uptake. Nat. Med., 2001; 7: 41-47
69. Morcos M., Sayed A.A., Bierhaus A., Yard B., Waldherr R., Merz W., Kloeting I., Schleicher E., Mentz S., Abd el Baki R.F., Tritschler H., Kasper M., Schwenger V., Hamann A., Dugi K.A., Schmidt A.M., Stern D., Ziegler R., Haering H.U., Andrassy M., van der Woude F., Nawroth P.P.: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes, 2002; 51: 3532-3544
70. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M.: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell, 1998; 93: 229-240
71. Nakagawa T., Nozaki S., Nishida M., Yakub J.M., Tomiyama Y., Nakata A., Matsumoto K., Funahashi T., Kameda-Takemura K., Kurata Y., Yamashita S., Matsuzawa Y.: Oxidized LDL increases and interferongamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol., 1998; 18: 1350-1357
72. Nakata A., Nakagawa Y., Nishida M., Nozaki S., Miyagawa J., Nakagawa T., Tamura R., Matsumoto K., Kameda-Takemura K., Yamashita S., Matsuzawa Y.: CD36, a novel receptor for oxidized lowdensity lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 1333-1339
73. Narkiewicz K., Strojek K., Pasierski T.: Epidemiologia cukrzycy i jej powikłań sercowo-naczyniowych. W: Diabetokardiologia, red. Narkiewicz K., Pasierski T., Pikto-Pietkiewicz W., Strojek K. Wydawnictwo Medycyna Praktyczna, Kraków 2004; 29-35
74. Nicholson A.C.: Expression of CD36 in macrophages and atherosclerosis. The role of lipid regulation of PPARg signaling. Trends Cardiovasc. Med., 2004; 14: 8-12
75. Nicholson A.C. Hajjar D.P.: CD36, oxidized LDL and PPARg: pathological interactions in macrophages and atherosclerosis. Vascul. Pharmacol., 2005; 41: 139-146
76. Nicholson A.C., Frieda S., Pearce A., Silverstein R.L.: Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler. Thromb. Vasc. Biol., 1995; 15: 269-275
77. Noushmehr H., D'Amico E., Farilla L., Hui H., Wawrowsky K.A., Mlynarski W., Doria A., Abmrad N.A., Perfetti R.: Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. Diabetes, 2005; 54: 472-481
78. Nozaki S., Kashiwagi H., Yamashita S., Nakagawa T., Kostner B., Tomiyama Y., Nakata A., Ishigami M., Miyagawa J., Kameda-Takemura K., Kurata Y., Matsuzawa Y.: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-defi-cient subjects. J. Clin. Invest., 1995; 96: 1859-1865
79. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med., 1997; 337: 230-236
80. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S., Nakayama H.: CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem., 2001; 276: 3195-3202
81. Orie N.N., Zidek W., Tepel M.: Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp. Clin. Endocrinol. Diabetes, 2000; 108: 175-180
82. Piconi L., Quagliaro L., Ceriello A.: Oxidative stress in diabetes. Clin. Chem. Lab. Med., 2003; 41: 1144-1149
83. Platt N., da Silva R.P., Gordon S.: Recognizing death: The phagocytosis of apoptotic cells. Trends Cell. Biol., 1998; 8: 365-372
84. Pravenec M., Landa V., Zidek V., Musilova A., Kazdova L., Qi N., Wang J., St Lezin E., Kurtz T.W.: Transgenic expression of CD36 in the spontaneously hypertensive rats is associated with amelioration of metabolic disturbances but has no effect on hypertension. Physiol. Res., 2003; 52: 681-688
85. Pravenec M., Landa V., Zidek V., Musilova A., Kren V., Kazdova L., Aitman T.J., Glazier A.M., Ibrahimi A., Abumrad N.A., Qi N., Wang J.M., St Lezin E.M., Kurtz T.W.: Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat. Genet., 2001; 27: 156-158
86. Prokop J.B., Musiał W.J., Skibińska E., Kinalska I.: Cukrzyca jako czynnik ryzyka chorób układu sercowo-naczyniowego, szczególnie choroby niedokrwiennej serca. Kardiologia po Dyplomie, 2005; 1: 6-13
87. Pyorala K., Hoffman R., Hanrath P.: Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary events as non-diabetic subjects with prior myocardial infarction. Eur. Heart J., 1999; 20: 473-475
88. Pyorala M., Miettinen H., Laakso M., Pyorala K.: Hypersulinemia predicts coronary heart disease risk in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation, 1998; 98: 398-404
89. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., Bulnes-Enriquez I., Jimenez X., Hernandez G., De La Rosa R., Chan Y., Yang H., Nicholas S.B., Modilevsky T., Yu K., Van Herle K., Castellani L.W., Elashoff R., Hsueh W.A.: Coronary vasomotor abnormalities in insulin-resistant individuals. Ann. Intern. Med., 2004; 140: 700-708
90. Renard C.B., Kramer F., Johansson F., Lamharzi N., Tannock L.R., von Herrath M.G., Chait A., Bornfeldt K.E.: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest., 2004; 114: 659-668
91. Reusch J.E.B.: Current concepts in insulin resistance, type 2 diabetes mellitus and the metabolic syndrome. Am. J. Cardiol., 2002; 90(Suppl.): 19G-26G
92. Ricote M., Li A.C., Willson T.M. Kelly C.J., Glass C.K.: The peroxisome proliferator-activated receptor-g is a negative regulator of macrophage activation. Nature, 1998; 391: 79-82
93. Rodrigues B., McNeill J.H.: The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc. Res., 1992; 26: 913-922
94. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L.: The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congres Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 2001; 17: 189-212
95. Sampson MJ., Davies I.R., Braschi S., Ivory K., Hughes D.A.: Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Atherosclerosis, 2003; 167: 129-134
96. Skibińska E., Sawicki R., Lewczuk A., Prokop J., Musiał W., Kowalska I., Mroczko B.: Homocysteina, jako czynnik ryzyka choroby niedokrwiennej serca u męzczyzn do 55 roku zycia z koronarograficznie potwierdzoną chorobą wieńcową. Kardiol. Pol., 2004; 60: 197-205
97. Smiley T., Oh P., Shane L.G.: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes-systematic review. Can. J. Cardiol., 2001; 17: 797-805
98. Spiegelman B.M.: PPAR-g in monocytes: less pain, any gain? Cell, 1998; 93: 153-155
99. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., Bayazeed B., Baron A.D.: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest., 1997; 100: 1230-1239
100. Stuhlinger M., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S.: Relationship between insulin resistance and an endogenous nitirc oxide inhibitor. JAMA, 2002; 287: 1420-1426
101. Susztak K., Ciccone E., McCue P., Sharma K., Böttinger E.P.: Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLOS Med., 2005; 2: 152-161
102. Tan K.C., Chow W.S., Ai V.H., Metz C., Bucala R., Lam K.S.: Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care, 2002; 25: 1055-1059
103. Tanaka T., Sohmiya K., Kawamura K.: Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J. Mol. Cell. Cardiol., 1997; 29: 121-127
104. Telejko B., Bachórzewska-Gajewska H.: Stabilna choroba niedokrwienna serca-odrębnos̈ci u chorych na cukrzycę. Kardiologia po Dyplomie, 2005; 1: 22-33
105. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M.: PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 1998; 93: 241-252
106. Tsuzura S., Ikeda Y., Suehiro T., Ota K., Osaki F., Arii K., Kumon Y., Hashimoto K.: Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism, 2004; 53: 297-302
107. Turner R.C., Millns H., Neil H., Stratton I.M., Manley S.E., Matthews D.R., Holman R.R.: Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998; 316: 823-828
108. Unno Y., Sakai M., Sakamoto Y., Kuniyasu A., Nakayama H., Nagai R., Horiuchi S.: Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun., 2004; 325: 151-156
109. Vogl-Willis C.A., Edwards I.J.: High glucose induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler. Thromb. Vasc. Biol., 2004; 24: 858-863
110. Wasty F., Alavi M.Z., Moore S.: Distributions of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia, 1993; 36: 316-322
111. Wei M., Gaskill S.P., Haffner S.M., Stern M.P.: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality, The San Antonio Heart Study. Diabetes Care., 1998; 21: 1167-1172
112. Wierusz-Wysocka B., Wysocki H.: Odmienny przebieg miazdzycy u osób z zaburzeniami gospodarki węglowodanowej. Kardiologia po Dyplomie, 2005; 1: 14-21
113. Wintergerst E.S., Jelk J., Rahner C., Asmis R.: Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur. J. Biochem., 2000; 267: 6050-6059
114. Yanai H., Chiba H., Morimoto M., Jamieson G.A., Matsuno K.: Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb. Haemost., 2000; 83: 786
115. Yesner L., Huh H.Y., Pearce S.F., Silverstein R.L.: Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol., 1996; 16: 1019-1025
116. Yip J., Facchini F.S., Reaven G.M.: Resistance to insulin mediated insulin disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab., 1998; 83: 2773-2776
117. Zeiher A.M., Fisslthaler B., Schray-Utz B., Busse R.: Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res., 1995; 76: 980-986
118. Ziyadeh F.N., Goldfarb S.: The diabetic renal tubulointerstitium. Curr. Top. Pathol., 1995; 88: 175-201